Development and evaluation of Inhalable particdes Containing  kanamycin monosulhate and pyrazinoic acid for the treatment of drug resistant tuberculosis.

Srivastava, Ashish; Misra, Amit (Guide)

dc.contributor.author	Srivastava, Ashish
dc.contributor.author	Misra, Amit (Guide)
dc.date.accessioned	2023-11-29T06:42:17Z
dc.date.available	2023-11-29T06:42:17Z
dc.date.issued	2019-08-22
dc.identifier.citation	Guide - Dr. Amit Misra, PhD Thesis Submitted to AcSIR , Ghaziabad, UP in 2019	en_US
dc.identifier.uri	http://dkr.cdri.res.in:8080/xmlui/handle/1/1749
dc.description	Guide- Dr. Amit Misra, PhD Thesis Submitted to AcSIR , Ghaziabad, UP in 2019 by Ashish Srivastava	en_US
dc.description.abstract	Tuberculosis (TB) remains a major health problem and a prime cause of global patient mortality throughout the world. Even after 90 years of vaccination and 60 years of advanced chemotherapy development, we are far away from eradicating the disease. All member states of the WHO and the UN pledged to eradicate TB by 2030 by reducing all TB deaths by 90% in the 2014 World Health Assembly. In developing nations and settings with limited resources, TB poses further challenges.	en_US
dc.language.iso	en	en_US
dc.publisher	PhD Theses submitted by the Research Scholars of CSIR-CDRI, Lucknow	en_US
dc.relation.ispartofseries	S-407;
dc.subject	Development, evaluation of inhalable praticdes, pyrazinoic acid, resistant tuberculosis.	en_US
dc.title	Development and evaluation of Inhalable particdes Containing kanamycin monosulhate and pyrazinoic acid for the treatment of drug resistant tuberculosis.	en_US
dc.type	Thesis	en_US